PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Current Quarter	$-0.4	Next Quarter	$-0.29
Current Year	$-1.54	Next Year	$-1.39
QoQ Growth	+27.5%	YoY Growth	+9.7%
3Y EPS CAGR	N/A	Target Price	$5.50
Consensus	Buy	Upside	+316.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PMVP	$1.32	+0.76%	167.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PMVP	$1.32	+0.8%	167.46K
3
4
5
6

PMVP

PMVP

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get PMV Pharmaceuticals Inc. Data in Excel

Get PMV Pharmaceuticals Inc. Data in Excel